Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation

Anikó Maráz, József Furák, Regina Pálföldi, József Eller, Erika Szántó, Z. Kahán, L. Thurzó, J. Molnár, L. Tiszlavicz, K. Hideghéty

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: The associations between B-cell lymphoma 2 (BCL-2) and multi-drug resistance associated P-glycoprotein (MDR1) expressions and chemoradiotherapy outcome of patients with non-small cell lung cancer (NSCLC) were analysed. Patients and Methods: Thirty-two NSCLC patients were treated with paclitaxel-based chemoradiotherapy. The tumour expressions of BCL-2 and MDR1 were analysed by means of immunohistochemistry with regard to the clinical response and survival data. Results: Partial remission and stable disease were achieved in 19 (59%) and 10 (31%) cases, respectively. Significant differences in progression-free survival were observed between responders and non-responders (13.7 vs. 6.0 months, p=0.028), and between patients with or without a gross tumour volume (GTV) shrinkage (GTV>50 13.7 vs. 6.0 months, p=0.009). Overexpression of BCL-2 and of MDR1 was observed in 6 (21.4%) cases each. Overexpression of both markers together was associated with poor response (GTV reduction: p=0.005; RECIST: p=0.023) and lower progression-free survival (overexpression of both, low expression of both, mixed: 3.1, 13.4, 4.1 months, respectively, p

Original languageEnglish
Pages (from-to)1431-1436
Number of pages6
JournalAnticancer Research
Volume31
Issue number4
Publication statusPublished - Apr 2011

Fingerprint

B-Cell Lymphoma
Paclitaxel
Lung Neoplasms
Tumor Burden
Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Multiple Drug Resistance
P-Glycoprotein
Immunohistochemistry
Survival
Neoplasms

Keywords

  • BCL-2
  • Lung cancer
  • MDR1
  • Paclitaxel-based chemoradiotherapy
  • Radiosensitivity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation. / Maráz, Anikó; Furák, József; Pálföldi, Regina; Eller, József; Szántó, Erika; Kahán, Z.; Thurzó, L.; Molnár, J.; Tiszlavicz, L.; Hideghéty, K.

In: Anticancer Research, Vol. 31, No. 4, 04.2011, p. 1431-1436.

Research output: Contribution to journalArticle

Maráz A, Furák J, Pálföldi R, Eller J, Szántó E, Kahán Z et al. Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation. Anticancer Research. 2011 Apr;31(4):1431-1436.
Maráz, Anikó ; Furák, József ; Pálföldi, Regina ; Eller, József ; Szántó, Erika ; Kahán, Z. ; Thurzó, L. ; Molnár, J. ; Tiszlavicz, L. ; Hideghéty, K. / Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation. In: Anticancer Research. 2011 ; Vol. 31, No. 4. pp. 1431-1436.
@article{eddf7c13ed314f3c90b0c6817c875580,
title = "Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation",
abstract = "Background: The associations between B-cell lymphoma 2 (BCL-2) and multi-drug resistance associated P-glycoprotein (MDR1) expressions and chemoradiotherapy outcome of patients with non-small cell lung cancer (NSCLC) were analysed. Patients and Methods: Thirty-two NSCLC patients were treated with paclitaxel-based chemoradiotherapy. The tumour expressions of BCL-2 and MDR1 were analysed by means of immunohistochemistry with regard to the clinical response and survival data. Results: Partial remission and stable disease were achieved in 19 (59{\%}) and 10 (31{\%}) cases, respectively. Significant differences in progression-free survival were observed between responders and non-responders (13.7 vs. 6.0 months, p=0.028), and between patients with or without a gross tumour volume (GTV) shrinkage (GTV>50 13.7 vs. 6.0 months, p=0.009). Overexpression of BCL-2 and of MDR1 was observed in 6 (21.4{\%}) cases each. Overexpression of both markers together was associated with poor response (GTV reduction: p=0.005; RECIST: p=0.023) and lower progression-free survival (overexpression of both, low expression of both, mixed: 3.1, 13.4, 4.1 months, respectively, p",
keywords = "BCL-2, Lung cancer, MDR1, Paclitaxel-based chemoradiotherapy, Radiosensitivity",
author = "Anik{\'o} Mar{\'a}z and J{\'o}zsef Fur{\'a}k and Regina P{\'a}lf{\"o}ldi and J{\'o}zsef Eller and Erika Sz{\'a}nt{\'o} and Z. Kah{\'a}n and L. Thurz{\'o} and J. Moln{\'a}r and L. Tiszlavicz and K. Hidegh{\'e}ty",
year = "2011",
month = "4",
language = "English",
volume = "31",
pages = "1431--1436",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation

AU - Maráz, Anikó

AU - Furák, József

AU - Pálföldi, Regina

AU - Eller, József

AU - Szántó, Erika

AU - Kahán, Z.

AU - Thurzó, L.

AU - Molnár, J.

AU - Tiszlavicz, L.

AU - Hideghéty, K.

PY - 2011/4

Y1 - 2011/4

N2 - Background: The associations between B-cell lymphoma 2 (BCL-2) and multi-drug resistance associated P-glycoprotein (MDR1) expressions and chemoradiotherapy outcome of patients with non-small cell lung cancer (NSCLC) were analysed. Patients and Methods: Thirty-two NSCLC patients were treated with paclitaxel-based chemoradiotherapy. The tumour expressions of BCL-2 and MDR1 were analysed by means of immunohistochemistry with regard to the clinical response and survival data. Results: Partial remission and stable disease were achieved in 19 (59%) and 10 (31%) cases, respectively. Significant differences in progression-free survival were observed between responders and non-responders (13.7 vs. 6.0 months, p=0.028), and between patients with or without a gross tumour volume (GTV) shrinkage (GTV>50 13.7 vs. 6.0 months, p=0.009). Overexpression of BCL-2 and of MDR1 was observed in 6 (21.4%) cases each. Overexpression of both markers together was associated with poor response (GTV reduction: p=0.005; RECIST: p=0.023) and lower progression-free survival (overexpression of both, low expression of both, mixed: 3.1, 13.4, 4.1 months, respectively, p

AB - Background: The associations between B-cell lymphoma 2 (BCL-2) and multi-drug resistance associated P-glycoprotein (MDR1) expressions and chemoradiotherapy outcome of patients with non-small cell lung cancer (NSCLC) were analysed. Patients and Methods: Thirty-two NSCLC patients were treated with paclitaxel-based chemoradiotherapy. The tumour expressions of BCL-2 and MDR1 were analysed by means of immunohistochemistry with regard to the clinical response and survival data. Results: Partial remission and stable disease were achieved in 19 (59%) and 10 (31%) cases, respectively. Significant differences in progression-free survival were observed between responders and non-responders (13.7 vs. 6.0 months, p=0.028), and between patients with or without a gross tumour volume (GTV) shrinkage (GTV>50 13.7 vs. 6.0 months, p=0.009). Overexpression of BCL-2 and of MDR1 was observed in 6 (21.4%) cases each. Overexpression of both markers together was associated with poor response (GTV reduction: p=0.005; RECIST: p=0.023) and lower progression-free survival (overexpression of both, low expression of both, mixed: 3.1, 13.4, 4.1 months, respectively, p

KW - BCL-2

KW - Lung cancer

KW - MDR1

KW - Paclitaxel-based chemoradiotherapy

KW - Radiosensitivity

UR - http://www.scopus.com/inward/record.url?scp=79956136147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956136147&partnerID=8YFLogxK

M3 - Article

C2 - 21508398

AN - SCOPUS:79956136147

VL - 31

SP - 1431

EP - 1436

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -